Evaluating Prophylactic Anticoagulant Therapy Effectiveness for Treating COVID-19 - a podcast by VA HSRD

from 2021-09-17T09:15

:: ::

In this episode, Dr. Christopher Rentsch, of the London School of Hygiene and Tropical Medicine and Yale University, talks about a <a href="https://www.bmj.com/content/372/bmj.n311" target="_blank">large-scale evaluation of the effectiveness of prophylactic anticoagulant therapy</a> for the treatment of COVID-19.<br><br>

Since the recording of this podcast, the largest trial to date, ACTIV-4, has found that initiating therapeutic anticoagulation compared to prophylactic anticoagulation provided additional benefit among patients hospitalized with COVID-19. Both Dr. Rentsch&rsquo;s study and the ACTIV-4 study found benefit in <a href="https://www.nejm.org/doi/10.1056/NEJMoa2105911" target="_blank">noncritically ill</a> patients yet not in <a href="https://www.nejm.org/doi/10.1056/NEJMoa2103417">critically ill</a> patients.

Further episodes of VA HSR

Further podcasts by VA HSRD

Website of VA HSRD